glp-1 multiple endocrine neoplasia receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal glp-1 multiple endocrine neoplasia The

As expected, the negative probe ( DapB ) did not produce detectable signals (Fig

Clinical trials have demonstrated hemoglobin A1c reductions of approximately 2% in diabetes patients, with weight loss ranging from 7-11% in diabetes trials (SURPASS) and 15-21% in obesity trials (SURMOUNT), depending on the dose administered and patient population

While these observational studies cannot prove causation, the consistency of the signal across different populations, healthcare systems, and analytical methods has strengthened the case for randomized trials

Not just nausea Another side effect of GLP-1 drugs is a decrease in thirst, which could be dangerous for people who are already losing lots of fluids from side effects like vomiting and diarrhea